Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 2
1982 1
1984 2
1986 1
1987 2
1988 1
1989 1
1990 1
1999 1
2002 1
2004 1
2005 1
2009 2
2011 4
2012 2
2013 1
2014 3
2015 1
2019 1
2020 2
Text availability
Article attribute
Article type
Publication date

Search Results

30 results
Results by year
Filters applied: . Clear all
Page 1
Three months of rifapentine and isoniazid for latent tuberculosis infection.
Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, Hackman J, Hamilton CD, Menzies D, Kerrigan A, Weis SE, Weiner M, Wing D, Conde MB, Bozeman L, Horsburgh CR Jr, Chaisson RE; TB Trials Consortium PREVENT TB Study Team. Sterling TR, et al. Among authors: Bozeman L. N Engl J Med. 2011 Dec 8;365(23):2155-66. doi: 10.1056/NEJMoa1104875. N Engl J Med. 2011. PMID: 22150035 Free article. Clinical Trial.
Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium.
Dorman SE, Goldberg S, Stout JE, Muzanyi G, Johnson JL, Weiner M, Bozeman L, Heilig CM, Feng PJ, Moro R, Narita M, Nahid P, Ray S, Bates E, Haile B, Nuermberger EL, Vernon A, Schluger NW; Tuberculosis Trials Consortium. Dorman SE, et al. Among authors: Bozeman L. J Infect Dis. 2012 Oct 1;206(7):1030-40. doi: 10.1093/infdis/jis461. Epub 2012 Jul 30. J Infect Dis. 2012. PMID: 22850121 Clinical Trial.
Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial.
Dorman SE, Savic RM, Goldberg S, Stout JE, Schluger N, Muzanyi G, Johnson JL, Nahid P, Hecker EJ, Heilig CM, Bozeman L, Feng PJ, Moro RN, MacKenzie W, Dooley KE, Nuermberger EL, Vernon A, Weiner M; Tuberculosis Trials Consortium. Dorman SE, et al. Among authors: Bozeman L. Am J Respir Crit Care Med. 2015 Feb 1;191(3):333-43. doi: 10.1164/rccm.201410-1843OC. Am J Respir Crit Care Med. 2015. PMID: 25489785 Free PMC article. Clinical Trial.
What is the most reliable solid culture medium for tuberculosis treatment trials?
Joloba ML, Johnson JL, Feng PJ, Bozeman L, Goldberg SV, Morgan K, Gitta P, Boom HW, Heilig CM, Mayanja-Kizza H, Eisenach KD. Joloba ML, et al. Among authors: Bozeman L. Tuberculosis (Edinb). 2014 May;94(3):311-6. doi: 10.1016/j.tube.2014.03.002. Epub 2014 Mar 19. Tuberculosis (Edinb). 2014. PMID: 24698569
How we determined the most reliable solid medium for studying treatment of tuberculosis.
Heilig CM, Feng PJ, Joloba ML, Johnson JL, Morgan K, Gitta P, Boom WH, Mayanja-Kizza H, Eisenach KD, Bozeman L, Goldberg SV. Heilig CM, et al. Among authors: Bozeman L. Tuberculosis (Edinb). 2014 May;94(3):317-22. doi: 10.1016/j.tube.2014.02.006. Epub 2014 Mar 4. Tuberculosis (Edinb). 2014. PMID: 24661816 Free PMC article. Clinical Trial.
Intermittent tuberculosis treatment for patients with isoniazid intolerance or drug resistance.
Reves R, Heilig CM, Tapy JM, Bozeman L, Kyle RP, Hamilton CD, Bock N, Narita M, Wing D, Hershfield E, Goldberg SV; Tuberculosis Trials Consortium. Reves R, et al. Among authors: Bozeman L. Int J Tuberc Lung Dis. 2014 May;18(5):571-80. doi: 10.5588/ijtld.13.0304. Int J Tuberc Lung Dis. 2014. PMID: 24903795 Clinical Trial.
High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: Study protocol for TBTC study 31/ACTG A5349 phase 3 clinical trial.
Dorman SE, Nahid P, Kurbatova EV, Goldberg SV, Bozeman L, Burman WJ, Chang KC, Chen M, Cotton M, Dooley KE, Engle M, Feng PJ, Fletcher CV, Ha P, Heilig CM, Johnson JL, Lessem E, Metchock B, Miro JM, Nhung NV, Pettit AC, Phillips PPJ, Podany AT, Purfield AE, Robergeau K, Samaneka W, Scott NA, Sizemore E, Vernon A, Weiner M, Swindells S, Chaisson RE; AIDS Clinical Trials Group and the Tuberculosis Trials Consortium. Dorman SE, et al. Among authors: Bozeman L. Contemp Clin Trials. 2020 Mar;90:105938. doi: 10.1016/j.cct.2020.105938. Epub 2020 Jan 22. Contemp Clin Trials. 2020. PMID: 31981713
Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis.
Dorman SE, Johnson JL, Goldberg S, Muzanye G, Padayatchi N, Bozeman L, Heilig CM, Bernardo J, Choudhri S, Grosset JH, Guy E, Guyadeen P, Leus MC, Maltas G, Menzies D, Nuermberger EL, Villarino M, Vernon A, Chaisson RE; Tuberculosis Trials Consortium. Dorman SE, et al. Among authors: Bozeman L. Am J Respir Crit Care Med. 2009 Aug 1;180(3):273-80. doi: 10.1164/rccm.200901-0078OC. Epub 2009 Apr 30. Am J Respir Crit Care Med. 2009. PMID: 19406981 Clinical Trial.
Reasons for non-participation in an international multicenter trial of a new drug for tuberculosis treatment.
Lamunu D, Chapman KN, Nsubuga P, Muzanyi G, Mulumba Y, Mugerwa MA, Goldberg S, Bozeman L, Engle M, Saukkonen J, Mastranunzio S, Mayanja-Kizza H, Johnson JL. Lamunu D, et al. Among authors: Bozeman L. Int J Tuberc Lung Dis. 2012 Apr;16(4):480-5. doi: 10.5588/ijtld.11.0434. Int J Tuberc Lung Dis. 2012. PMID: 22640513 Free PMC article. Clinical Trial.
Mycobacterium tuberculosis specific CD8(+) T cells rapidly decline with antituberculosis treatment.
Nyendak MR, Park B, Null MD, Baseke J, Swarbrick G, Mayanja-Kizza H, Nsereko M, Johnson DF, Gitta P, Okwera A, Goldberg S, Bozeman L, Johnson JL, Boom WH, Lewinsohn DA, Lewinsohn DM; Tuberculosis Research Unit and the Tuberculosis Trials Consortium. Nyendak MR, et al. Among authors: Bozeman L. PLoS One. 2013 Dec 4;8(12):e81564. doi: 10.1371/journal.pone.0081564. eCollection 2013. PLoS One. 2013. PMID: 24324704 Free PMC article. Clinical Trial.
30 results
Jump to page
Feedback